Boron Biologicals Inc. of Raleigh, N.C., announced Friday that ithas received a $500,000 research contract from the NationalInstitutes of Health (NIH) to expand its research anddevelopment of novel boron compounds.
The Phase II Small Business Innovation Research (SBIR) grantwill fund research focused on modifying phosphates withboron-containing nucleic acids. "Our goal is to demonstrate thatboron-containing biomolecules can be highly effective anti-tumor and anti-viral agents," said Charles Krause, presidentand chief operating officer of Boron Biologicals.
(c) 1997 American Health Consultants. All rights reserved.